Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vestronidase Alfa · Mepsevii, UX-003

Recombinant protein · Protein replacement · developed by Ultragenyx Pharm

Approved FDA, Nov 2017
RARE Developer
1 Registered trials

What is Vestronidase Alfa?

Vestronidase alfa is a recombinant form of human beta-glucuronidase (GUS) given to replace the deficient enzyme. Its mannose-6-phosphate residues allow uptake into cell lysosomes, where it helps break down accumulated glycosaminoglycans. It is used to treat mucopolysaccharidosis VII (Sly syndrome).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Mepsevii, UX-003
Drug type
Recombinant protein
Mechanism
Protein replacement
Pathways
Mannose-6-phosphate receptor-mediated cellular uptake, Lysosomal glycosaminoglycan catabolism
Therapy area
Metabolic
Developer
Ultragenyx Pharm Inc (RARE)
FDA status
Approved as Mepsevii (November 15, 2017), BLA761047 · FDA label
UNII
7XZ4062R17

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 18, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03775174 N/A MPS VII Available RARE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MPS VIIMucopolysaccharidosis VIISly Syndrome

More from Ultragenyx Pharm

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RARE page.

Follow RARE, the company behind Vestronidase Alfa

See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RARE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.